An analysis considering the co-expression of adaptive markers in controls and MS patients showed that antibody-triggered responses were greater in NKG2C(+) CD56dim NK cells independently of FcRγ or PLZF expression (Supplementary Figure 5). This evidence concerns the gene ZBTB16 and myeloid sarcoma.